Biomarker Technologies Market

Biomarker Technologies Market Outlook - 2026

The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026. 

Biomarker is a biological characteristic which is measured and evaluated as a maker of normal biological or pathological processes or a response to a therapeutic intervention. For instance, patterns of gene expression are used to identify various diseases. There are different biomarkers, which can be identified by using different technologies such as polymerase chain reaction, next generation sequencing, immunoassay, and others. Biomarkers are extensively used in diagnosis of various diseases such as cancer, infectious diseases, autoimmune diseases, and others. This is due to their property of marking the biological changes associated with these diseases. Moreover, biomarkers are also employed in the drug development process as these can mark early toxicity associated with drugs in the early phases of drug development. In addition, as these provide sensitive data related to disease progression, biomarkers are also employed in personalized medicine. 

The global biomarker technologies market is expected to witness significant growth during the forecast period, owing to increase in prevalence of various diseases and rise in R&D activities in healthcare coupled with surge in adoption of early toxicity testing. In addition, advantages offered by biomarker in drug development and increase in genome mapping programs. However, high initial capital investments required for biomarker discovery, and lack of awareness regarding the use of biomarker technologies hamper the growth of biomarker technologies market. Furthermore, high potential of the emerging economies is expected to provide opportunities for the growth of the biomarker technologies market during the forecast period.

Biomarker Technologies Market Segmentation  

The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product & service, the market is divided into consumables, instruments, and services. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. Based on application, the market is classified into drug discovery, diagnostics, and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).

Segment review

Based on product & service, the market is divided into consumables, instruments, and services. The consumables segment was the largest contributor to the biomarker technologies market in 2018 and is expected to maintain its dominant position throughout the analysis period. Consumables are crucial part of biomarker testing and are required for performing various technologies. Therefore, this leads to the growth of this market. On the other side, the instruments segment is the fastest growing segment during the forecast period, owing to the technological advancements, which have rendered these instruments more precise and quick. Moreover, the rise in adoption of biomarker technologies across various fields of science is another factor that contributes to the biomarker technologies market growth. 

According to the biomarker technologies market analysis, the technology segment is classified into polymerase chain reaction (PCR), next generation sequencing (NGS), immunoassay, and others. The immunoassay segment occupied the highest share of the biomarker technologies market size in 2018. Next generation sequencing (NGS) segment registered fastest growth rate during the forecast period, owing to surge in research related to cancer as next generation sequencing is applied in analyzing differences between cancers that otherwise seem identical.

Region wise, Asia-Pacific accounted for the largest biomarker technologies market share in 2018 owing to surge in R&D related to drug discovery, easy availability of instruments and consumables, availability of trained technicians and high prevalence of diseases such as cancer and autoimmune diseases. Asia-Pacific is expected to register the fastest growth during the forecast period due to rise in awareness related to early screening of cancer for better treatment, increase in disposable income, and surge in R&D investments related to healthcare.

The report provides an extensive competitive analysis and profiles of the key market players such as Agilent Technologies, Inc., Bio-Rad Laboratories, Inc.,  F. Hoffmann-La Roche AG, Illumina, Inc., LI-COR, Inc., Merck KGAA, PerkinElmer Inc., QIAGEN, Shimadzu Corporation, and Thermo Fisher Scientific, Inc.

Key Benefits for Biomarker Technologies Market:

• This report entails a detailed quantitative analysis along with the current biomarker technologies market trends of the market from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment of the global market. 
• The biomarker technologies market forecast is studied from 2019 to 2026. 
• The market size and estimations are based on a comprehensive analysis of key developments in the biomarker technologies industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

 Biomarker Technologies Market Report Highlights